<DOC>
	<DOC>NCT00689338</DOC>
	<brief_summary>To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.</brief_summary>
	<brief_title>Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>ICU patients with a diagnosis of documented candidemia or invasive candidiasis and belonging to one or more of the following specific populations: Postabdominal surgery. Elderly &gt; 65 years old. Renal insufficiency / failure / hemodialysis. Solid tumor. Solidorgan (liver, kidney, lung, heart) transplant recipients. Hepatic insufficiency. Neutropenic including hematology oncology patients. Patients with poor venous access that would preclude IV drug delivery or multiple blood draws.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Candida</keyword>
	<keyword>Candidemia</keyword>
	<keyword>Systemic Candidiasis</keyword>
	<keyword>ICU</keyword>
	<keyword>Intensive Care Unit</keyword>
	<keyword>Critical Care Unit</keyword>
	<keyword>Anidulafungin</keyword>
	<keyword>Ecalta</keyword>
	<keyword>Eraxis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Voriconazole</keyword>
</DOC>